Paradigm Biopharma engages Danish firm to expand Phase 3 knee OA trial

Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical Development to expand the scope of its Phase Three trial using its flagship product to treat osteoarthritis in knee joints.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Disclaimer: This content has been prepared as part of a partnership with Paradigm Biopharma Ltd and is intended for informational purposes only.

As part of the NBCD engagement, Paradigm is expanding its Phase III to Moldova and Hong Kong, with the latter jurisdiction seeing the trial streamlined under that region’s “1+” regulatory pathway.

The Moldova sites, meanwhile, Paradigm reports, offer access to medical infrastructure and “a patient population suited to OA studies.”

On Wednesday, Paradigm cited NBCD’s “deep expertise in musculoskeletal and osteoarthritis trials,” with NBCD having previously led OA trials.

All in all, the Phase III trials have seen 60 sites globally activated, with Hong Kong and Moldova to go live in December; recruitment kicks off in January 2026.

“NBCD brings deep musculoskeletal and OA trial experience, and the addition of these strategically chosen sites strengthens both the scientific and operational foundations of our pivotal Phase 3 program,” PAR Chief Medical Officer Dr Donna Skerrett said.

“We are pleased to welcome NBCD as a partner working alongside Advanced Clinical and our internal clinical operations team…Hong Kong, in particular, provides a meaningful bridge to the Greater Bay Area under the new ‘1+’ framework, creating future regulatory and commercial optionality.”

PAR last traded at 38.5cps; YTD returns are up +70%.

Join the discussion: See what HotCopper users are saying about Paradigm Biopharma Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.